In mid-stage CKD patients, although kidney function is partially impaired, SGLT-2 inhibitors continue to improve kidney outcomes through mechanisms such as enhancing renal metabolism, reducing oxidative stress and inflammation, and lowering proteinuria. This evidence concerns the gene SLC5A2 and chronic kidney disease.